1. Home
  2. Search

Search

Search results

11 results found

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.

Publication: Journal Article
Cheifetz, Adam S, Maria T Abreu, Waqqas Afif, Raymond K Cross, Marla C Dubinsky, Edward Loftus V, Mark T Osterman, et al. 2021. “A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.”. The American Journal of Gastroenterology 116 (10): 2014-25.

Umadevi Ramesh, Psy.D.

Person: Post-Doctoral Clinical Psychology Fellow, BIDMC
Umadevi Ramesh, PsyD is a post-doctoral clinical psychology fellow in the Inflammatory Bowel Disease (IBD) Center. She serves as the lead clinician on a quality improvement initiative focused on developing and implementing group-based behavioral therapy programs for patients with IBD. Dr. Ramesh...

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.

Publication: Journal Article
Papamichael, Konstantinos, Adam S Cheifetz, Gil Y Melmed, Peter M Irving, Niels Vande Casteele, Patricia L Kozuch, Laura E Raffals, et al. 2019. “Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.”. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association 17 (9): 1655-1668.e3.

Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.

Publication: Journal Article
Papamichael, Konstantinos, Niels Vande Casteele, Jenny Jeyarajah, Vipul Jairath, Mark T Osterman, and Adam S Cheifetz. 2021. “Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease: An ACCENT-II Post Hoc Analysis.”. The American Journal of Gastroenterology 116 (5): 1007-14.

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).

Publication: Journal Article
Papamichael, Konstantinos, Vipul Jairath, Guangyong Zou, Benjamin Cohen, Timothy Ritter, Bruce Sands, Corey Siegel, et al. 2022. “Proactive Infliximab Optimisation Using a Pharmacokinetic Dashboard versus Standard of Care in Patients With Crohn’s Disease: Study Protocol for a Randomised, Controlled, Multicentre, Open-Label Study (the OPTIMIZE Trial).”. BMJ Open 12 (4): e057656.

Davide De Marco, M.D.

Person: Inflammatory Bowel Disease Fellow
Born and raised in Montreal, Davide attended McGill Medical School where he graduated in 2020. He then went on to complete internal medicine and gastroenterology and hepatology residency at McGill in 2025. He is currently enrolled in the Beth Israel Deaconess Medical Center Advanced Inflammatory...